Failure of beta interferon therapy in X-linked adrenoleukodystrophy

1996 ◽  
Vol 155 (9) ◽  
pp. 833-833 ◽  
Author(s):  
G. C. Korenke ◽  
H. -J. Christen ◽  
D. H. Hunneman ◽  
F. Hanefeld
Author(s):  
Sureshkumar Radhakrishnan ◽  
PraveenKumar Yadav ◽  
Anandakuttan Anandkumar ◽  
Emmanuel James ◽  
RajeswaryKalathil Padmajan

1995 ◽  
Vol 56-63 ◽  
pp. 35-35
Author(s):  
C. Gasperini ◽  
T. Koudriatseva ◽  
C. Pozzilli ◽  
S. Bastianello ◽  
A. Colleluon ◽  
...  

1994 ◽  
Vol 87 (4) ◽  
pp. 519-524
Author(s):  
Yoshihiro DAKE ◽  
Takaaki KAWAGUCHI ◽  
Yutaka KATO ◽  
Takaaki KIMURA

Haemophilia ◽  
1996 ◽  
Vol 2 (2) ◽  
pp. 104-108 ◽  
Author(s):  
T. HAGIWARA ◽  
H. FUKUE ◽  
K. KAWATA ◽  
T. YAMAGISHI ◽  
Y. YAMAMOTO ◽  
...  

2005 ◽  
Vol 79 (17) ◽  
pp. 11045-11052 ◽  
Author(s):  
Aimee L. Anderson ◽  
Krista E. Banks ◽  
Marco Pontoglio ◽  
Moshe Yaniv ◽  
Alan McLachlan

ABSTRACT Treatment with alpha interferon is a standard therapy for patients with chronic hepatitis B virus (HBV) infections. This treatment can reduce virus load and ameliorate disease symptoms. However, in the majority of cases, alpha interferon therapy fails to resolve the chronic HBV infection. The reason alpha interferon therapy is inefficient at resolving chronic HBV infections is assumed to be because it fails to eliminate covalently closed circular (CCC) HBV DNA from the nuclei of infected hepatocytes. In an attempt to address this issue, the stability of HBV CCC DNA in response to alpha/beta interferon induction was examined in HNF1α-null HBV transgenic mice. Alpha/beta interferon induction by polyinosinic-polycytidylic acid [poly(I-C)] treatment efficiently eliminated encapsidated cytoplasmic HBV replication intermediates while only modestly reducing nuclear HBV CCC DNA. These observations indicate that nuclear HBV CCC DNA is more stable than cytoplasmic replication intermediates in response to alpha/beta interferon induction. Consequently it appears that for therapies to resolve chronic HBV infection efficiently, they will have to target the elimination of the most stable HBV replication intermediate, nuclear HBV CCC DNA.


1989 ◽  
Vol 71 (5) ◽  
pp. 639-641 ◽  
Author(s):  
M. Stephen Mahaley ◽  
Edward J. Dropcho ◽  
Linda Bertsch ◽  
Tammy Tirey ◽  
G. Yancey Gillespie

✓ Recombinant beta-interferon in escalating dosages was administered intravenously three times weekly to seven patients with recurrent gliomas. No evidence of response was seen in any patient, either on neurological examination or by computerized tomography (CT). However, stabilization of tumor volume, assessed from contrast-enhanced CT scans, occurred for 8 to 26 weeks in three patients. Immediate progression of disease despite treatment occurred in four patients.


Sign in / Sign up

Export Citation Format

Share Document